Anaconda Biomed Receives IDE Approval to Initiate Enrollment in the ATHENA Study
Anaconda Biomed S.L., a medical technology company developing next-generation thrombectomy systems, has announced that it has received conditional IDE approval from the U.S. Food and Drug Administration to begin the ATHENA study of its ANA Funnel Catheter. The prospective, randomized, dual-arm, multi-center study will assess the safety and effectiveness of mechanical thrombectomy using the ANA Funnel Catheter in combination with a stent retriever.